What changed
Adjusted EPS of $3.82 topped the $3.77 consensus by $0.05 (+1.3%), with results absorbing a $0.11 per-share hit from acquired IPR&D and milestones expense. Revenue came in at $17.404B, up 10.3% YoY (10.5% operational), as immunology net revenues rose 16.3% on the back of Skyrizi's $5.776B (+22.7%) and Rinvoq's $2.706B (+23.9%). Management raised FY2026 adjusted EPS guidance to $13.95–$13.99 from $13.76–$13.96, a range that includes the $0.69 per-share YTD IPR&D and milestones drag.
Why it matters
Adjusted EPS of $3.82 topped the $3.77 consensus by $0.05 (+1.3%), with results absorbing a $0.11 per-share hit from acquired IPR&D and milestones expense. Revenue came in at $17.404B, up 10.3% YoY (1